Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Takeda Pharmaceutical : Bracing for 383-B.-Yen Net Loss for FY 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 06:40am EDT

Takeda Pharmaceutical Co. said Tuesday that it expects to incur a consolidated net loss of 383 billion yen in fiscal 2019 to next March, compared with the 109,126-million-yen net profit in the previous year.

The bottom line will be dented by 796 billion yen due to an accounting factor related to the Japanese drug maker's 6.2-trillion-yen acquisition of major Irish peer Shire PLC in January. Specifically, Takeda reevaluated inventories at Shire at market value.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
SHIRE 2.42% 4690 End-of-day quote.0.00%
TAKEDA PHARMACEUTICAL CO LTD 1.09% 3798 End-of-day quote.4.92%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL CO L
09/20TAKEDA PHARMACEUTICAL : and Lundbeck announce Ministry of Health, Labour and Wel..
PU
09/20H LUNDBECK : Lundbeck and Takeda announce Ministry of Health, Labour and Welfare..
AQ
09/19TAKEDA PHARMACEUTICAL : Recognized in the 2019 Dow Jones Sustainability World In..
BU
09/16TAKEDA PHARMACEUTICAL : Message about the US NATPARA Recall
AQ
09/06TAKEDA PHARMACEUTICAL : Issues US Recall of NATPARA for Injection Due to the Pot..
AQ
09/06SUMITOMO DAINIPPON PHARMA : investing $3 billion in Swiss Roivant in overseas pu..
RE
09/06TAKEDA PHARMACEUTICAL COMPANY LIMITE : Takeda Issues US Recall of NATPARA(R) (pa..
EQ
09/05TAKEDA PHARMACEUTICAL : Issues US Recall of NATPARA® (parathyroid hormone) for I..
AQ
08/28FRESENIUS MEDICAL CARE : Names New Chief Financial Officer
DJ
08/27Fresenius Medical Care appoints Takeda executive Helen Giza as CFO
RE
More news
Financials (JPY)
Sales 2020 3 329 B
EBIT 2020 -37 767 M
Net income 2020 -301 163 M
Debt 2020 4 305 B
Yield 2020 4,74%
P/E ratio 2020 -19,6x
P/E ratio 2021 36,8x
EV / Sales2020 3,07x
EV / Sales2021 2,90x
Capitalization 5 919 B
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 5 235,00  JPY
Last Close Price 3 798,00  JPY
Spread / Highest target 65,9%
Spread / Average Target 37,8%
Spread / Lowest Target -2,58%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD4.92%54 842
JOHNSON & JOHNSON0.82%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVARTIS15.60%199 009